Company Overview

Maze Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing precision medicines for genetically defined patient populations. The company operates within the biopharmaceutical and genomics-driven drug discovery industries, with a core emphasis on leveraging human genetics to identify novel therapeutic targets and de-risk drug development. Its primary revenue drivers to date are research collaborations and upfront or milestone-based payments, as the company does not yet have commercialized products.

Maze Therapeutics was founded in 2018 and built its platform around the systematic analysis of large-scale human genetic datasets to uncover disease-causing pathways that can be modulated with small-molecule therapies. The company’s strategy centers on translating strong genetic evidence into medicines for chronic kidney disease, cardiovascular disease, and metabolic disorders, positioning Maze as a differentiated player in target discovery and early clinical development.

Business Operations

Maze Therapeutics conducts operations primarily through its integrated research and development organization, which spans target discovery, preclinical development, and early-stage clinical trials. The company’s core business activities are organized around its proprietary Compass Platform, which combines human genetics, functional genomics, and data science to identify and validate drug targets with a higher probability of clinical success. Revenue generation is currently non-recurring and tied to strategic collaborations rather than product sales.

The company operates mainly in the United States and controls its discovery and development programs internally, while selectively partnering for certain research initiatives. Maze has entered into collaboration agreements with larger pharmaceutical companies to apply its platform to specific disease areas, retaining ownership or co-ownership of resulting assets in some cases. Data on the full financial contribution of these partnerships is limited in public disclosures.

Strategic Position & Investments

Maze Therapeutics’ strategic direction is centered on advancing a pipeline of small-molecule therapeutics informed by human genetics into mid-stage clinical development. Growth initiatives focus on expanding its internal pipeline in kidney and cardiovascular diseases while continuing to validate its platform through external partnerships. The company has invested heavily in computational biology, high-throughput functional genomics, and translational science to support this strategy.

The company’s pipeline includes multiple development-stage programs targeting genetically validated pathways, with lead assets progressing through early clinical evaluation. Maze does not publicly disclose a broad portfolio of subsidiaries or external equity investments, and available public information does not indicate material acquisitions to date. Data inconclusive based on available public sources regarding late-stage clinical timelines and commercialization plans.

Geographic Footprint

Maze Therapeutics is headquartered in South San Francisco, California, a major biotechnology hub within the United States. Its primary research, development, and corporate operations are conducted from this location, with access to regional scientific talent and infrastructure.

While the company’s operational footprint is predominantly domestic, its research activities and collaborations have global relevance due to the use of international genetic datasets and potential future clinical trial sites outside the United States. As of the latest publicly available information, Maze does not report significant owned facilities or subsidiaries in other global regions.

Leadership & Governance

Maze Therapeutics was founded by a group of scientists and entrepreneurs with expertise in genetics, drug discovery, and company building. The leadership team emphasizes a science-driven culture focused on rigorous genetic validation and long-term value creation through precision medicine.

Key executives include:

• Jason Coloma – Chief Executive Officer
• Ann E. Woolley – Chief Financial Officer
• Stephen C. Friedman – Chief Medical Officer
• Matthew Nelson – Chief Scientific Officer
• Jason Heinz – Chief Operating Officer

The company is governed by a board of directors composed of senior biotechnology executives and investor representatives, reflecting a strategic vision centered on disciplined clinical advancement and partnership-driven growth.